SPAG6 and breast carcinoma: A combination of SPAG6 and NKX2-6 revealed a sensitivity of 27% for breast cancer detection (cut-off methylation 6.9%, 85% specificity), which could be increased to 31% using a combination of SPAG6 and PER1 (cut-off 7.7%, 85% specificity).